Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor.

Published byかんじ こうじょう Modified over 5 years ago

Similar presentations

Presentation on theme: "A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor."— Presentation transcript:

1 A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly  Swan Swan Leong, MD, Chee Keong Toh, MD, Wan Teck Lim, MD, Xu Lin, PhD, Say Beng Tan, PhD, Donald Poon, MD, Miah Hiang Tay, MD, Kian Fong Foo, MD, Juliana Ho, MD, Eng Huat Tan, MD  Journal of Thoracic Oncology  Volume 2, Issue 3, Pages (March 2007) DOI: /JTO.0b013e318031d06f Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Quality of Life-Cancer 30 Questionnaire (version 3.0) global health scores by treatment groups. QoL, quality of life; GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Quality of Life Questionnaire Lung Cancer–Specific Module scores by treatment group. QoL, quality of life; GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Quality of Life Questionnaire Lung Cancer–Specific Module question 3 scores by Eastern Cooperative Oncology Group (ECOG) status. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Progression-free survival by treatment group. GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Overall survival by treatment group. GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, DOI: ( /JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,
Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized.

Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized.
Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized.

Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients  Natalia Sutiman, BSc, Shao.

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients  Natalia Sutiman, BSc, Shao.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium 

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium 
A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.
Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.

Similar presentations

Ads by Google